Clinical Trial Update: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of selinexor, carfilzomib, and dexamethasone in relapsed or refractory multiple myeloma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib) (carfilzomib)
• XPOVIO (selinexor) (selinexor)

Snippet

Sponsor: University of Chicago | Conditions: Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED